Preparation and in vitro studies of MRI-specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4593-4611

  Li, Youwei ^a,b   Chen, Zhengguang ^c   Li, Fei ^a   Wang, Jichen ^d   Zhang, Zongming ^a,e  

^a Tsinghua University   (China)

^b BEIJING CHUIYANGLIU HOSPITAL   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d THE AFFILIATED BENQ HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^e GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; HepG2 cells; Magnetic resonance imaging; Superparamagnetic iron oxide antiGPC3 USPIO probe

Indexed keywords

ALPHA FETOPROTEIN ANTIBODY; ALPHA FETOPROTEIN RECEPTOR; CARBOXYLIC ACID; DEXTRAN; GLYPICAN 3; GLYPICAN 3 RECEPTOR; IRON; MONOCLONAL ANTIBODY; RECEPTOR; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; HYDRODYNAMICS; IMAGE ANALYSIS; IN VITRO STUDY; INCUBATION TIME; LIVER CELL CARCINOMA; MOLECULAR IMAGING; NANOPROBE; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY;

ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DEXTRANS; GLYPICANS; HEP G2 CELLS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MOLECULAR PROBES;

EID: 84870354923     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S32196     Document Type: Article

References (35)

1. Man XB, Tang L, Zhang BH, etal. Upregulation of glypican-3 expression in hepatocellular carcinomas but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int. 2005;25:962-966.
2. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008;7:237-257.
3. Reimer P, Weissleder R, Wittenberg J, Brady TJ. Receptor directed contrast agents for MR imaging: preclinical evaluation with affinity assays. Radiology. 1992;182:565-569.
4. Jia FG, Zhang XD, Xu YK, Meng Z. Synthesis of Gal-BSA-SPIO and magnetic resonance imaging of ASG receptors in rabbits bearing liver VX2 tumor and human liver. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29:191-194. Chinese.
5. Lee CM, Jeong HJ, Kim EM, etal. Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo. Magn Reson Med. 2009;62:1440-1446.
6. Huo T, Du X, Zhang S, Liu X, Li X. Gd-EDDA/HYNIC-RGD as an MR molecular probe imaging integrin αvβ3 receptor-expressed tumor-MR molecular imaging of angiogenesis. Eur J Radiol. 2010;73:420-427.
7. Wang XD, Wu GQ, Ju HS, etal. Preparation of MR molecular probe targeting integrin αvβ3 receptor and its in vitro imaging. J Southeast Uni (Med Sci Edi). 2009;28:470-473.
8. Corbin IR, Li H, Chen J, etal. Low-density lipoprotein as magnetic resonance imaging contrast agents. Neoplasia. 2006;8:488-498.
9. Crich SG, Lanzardo S, Alberti D, etal. Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia. 2007;9:1046-1056.
10. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev. 1987;87: 901-927.
11. Rosenthal SG, Willich HC, Ebert W, Conrad J. The demonstration of human tumors on nude mice using gadolinium-labeled monoclonal antibodies for magnetic resonance imaging. Invest Radiol. 1993;28: 789-793.
12. Renshaw PF, Owen CS, McLaughlin AC, Frey TG, Leigh LS Jr. Ferromagnetic contrast agents: a new approach. Magn Reson Med. 1986;3:217-225.
13. Srivastava S, Gopal Srivastava R. Biomarkers in cancer screening: a public health perspective. J Nutr. 2002;132:2471S-2475S.
14. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273-278.
15. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keefe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology. 2002;36:410-417.
16. Soresi M, Magliarisi C, Campagna P, etal. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747-1753.
17. Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007;45:1169-1179.
18. Kandil D, Leiman G, Allegretta M, etal. Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007;111:316-322.
19. Ligato S, Mandich D, Cartun RW. Utility of glypican-3in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Mod Pathol. 2008;21:626-631.
20. Leuschner C, Kumar CS, Hansel W, Soboyejo, Zhou J, Hormes J. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat. 2006;99:163-176.
21. Hermanson GT. Polymeric microspheres and nanoparticles. In: Bioconjugate Techniques. 2nd ed. New York, NY: Academic Press; 2008.
22. Funovics MA, Kapeller B, Hoeller C, etal. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging. 2004;22:843-850.
23. de Freitas ER, Soares PR, Santos R de P, etal. In vitro biological activities of anionic gamma-Fe2O3 nanoparticles on human melanoma cells. J Nanosci Nanotechnol. 2008;8:2385-2391.
24. Mahmoudi M, Simchi A, Milani AS, etal. Cell toxicity of superparamagnetic iron oxide nanoparticles. J Colloid Interface Sci. 2009;336:510-518.
25. Wu X, Tan Y, Mao H, Zhang M. Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int J Nanomedicine. 2010;5:385-399.
26. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials. 2003;24:1001-1011.
27. Ma YJ, Gu HC. Study on the endocytosis and the internalization mechanism of aminosaline-coated Fe3O4 nanoparticles in vitro. J Mater Sci Mater Med. 2007;18:2145-2149.
28. Billotey C, Wilhelm C, Devaud M, Bacri JC, Bittoun J, Gazeau F. Cell internalization of anionic maghemite nanoparticles: quantitative effect on magnetic resonance imaging. Magn Reson Med. 2003;49: 646-654.
29. Cedervall T, Lynch I, Lindman S, etal. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A. 2007;104:2050-2055.
30. Mahmoudi M, Simchi A, Imani M, etal. A new approach for the in vitro identification of the cytotoxicity of superparamagnetic iron oxide nanoparticles. Colloids Surf B Interfaces. 2010;75:300-309.
31. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell "sees" in bionanoscience. J Am Chem Soc. 2010;132:5761-5768.
32. Tseng HH, Chang JG, Hwang YH, Yeh KT, Chen YL, Yu HS. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol. 2009;135:1413-1420.
33. Dawson KA, Salvati A, Lynch I. Nanotoxicology: nanoparticles reconstruct lipids. Nat Nanotechnol. 2009;4:84-85.
34. Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials. 2002;23:1553-1561.
35. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003;63:8122-8125.